Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery.
Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery.
复制标题
DOI：
10.1155/2015/537560
复制
发表时间：
2015
影响因子：
--
通讯作者：
Ghatak S
中科院分区：
文献类型：
--
作者：
Misra S;Hascall VC;Atanelishvili I;Moreno Rodriguez R;Markwald RR;Ghatak S
在过去的十年中，随着靶向细胞表面粘附受体、受体酪氨酸激酶的药物的掺入以及细胞外基质（ECM）的几种分子的调节，癌症患者的结局得到了显著改善，ECM是胶原蛋白、糖蛋白、蛋白聚糖和糖胺聚糖的复杂复合物，决定了组织结构。癌组织侵袭过程通过各种致癌策略进行，包括干扰ECM分子及其与侵袭细胞的相互作用。在这篇综述中，我们描述了ECM成分，蛋白多糖和糖胺聚糖，如何影响肿瘤细胞信号。特别是这篇综述描述了糖胺聚糖透明质酸（HA）及其主要受体CD44如何影响肿瘤细胞的侵袭行为，并提供了有用的见解时，设计新的治疗策略在治疗癌症。
The outcome of patients with cancer has improved significantly in the past decade with the incorporation of drugs targeting cell surface adhesive receptors, receptor tyrosine kinases, and modulation of several molecules of extracellular matrices (ECMs), the complex composite of collagens, glycoproteins, proteoglycans, and glycosaminoglycans that dictates tissue architecture. Cancer tissue invasive processes progress by various oncogenic strategies, including interfering with ECM molecules and their interactions with invasive cells. In this review, we describe how the ECM components, proteoglycans and glycosaminoglycans, influence tumor cell signaling. In particular this review describes how the glycosaminoglycan hyaluronan (HA) and its major receptor CD44 impact invasive behavior of tumor cells, and provides useful insight when designing new therapeutic strategies in the treatment of cancer.